Alnylam Pharmaceuticals Overview and Financial Performance

Alnylam Pharmaceuticals has established itself as a leader in the RNAi therapeutics field, with a focus on developing treatments for rare genetic diseases. Founded in 2002, the company has made significant strides in advancing its pipeline of innovative therapies.

With a strong financial foundation, Alnylam has been able to invest heavily in research and development, with a focus on bringing new treatments to market. The company's financial performance has been impressive, with significant revenue growth in recent years.

Alnylam's commitment to innovation and research has led to the development of several groundbreaking therapies, including Onpattro, which was approved by the FDA in 2018. This approval marked a major milestone for the company and cemented its position as a leader in the RNAi therapeutics field.

Intriguing read: Qualities of a Good Leader

Alnylam Pharmaceuticals has a strong presence in the regulatory and financial landscape. The company has received numerous regulatory approvals for its RNAi therapeutics, including the approval of patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.

Alnylam has also made significant strides in its financial performance, with revenue growth driven by the commercialization of its products. In 2020, the company reported revenue of $1.1 billion, a 34% increase from the previous year.

The company's financial stability has enabled it to invest in research and development, with a focus on expanding its pipeline of RNAi therapeutics.

The company's profitability is a concern, with a profit margin of -12.96% indicating a significant loss.

Revenue is substantial, reaching $2.46 billion in the trailing twelve months.

The company's return on assets is also a red flag, coming in at -2.63%.

Net income available to common shareholders has taken a hit, sitting at -$319.09 million in the trailing twelve months.

Diluted earnings per share (EPS) are negative, at -$2.51.

Here's a breakdown of the company's cash and debt situation:

Staying on top of catalyst impacts is crucial for any company looking to stay ahead of the competition. Proactively evaluating catalysts can help you anticipate and capitalize on opportunities that others may miss.

Alnylam Pharmaceuticals Inc is a great example of a company that benefits from a catalyst calendar. By evaluating their catalyst impacts, you can improve corporate planning and bolster business development with timely opportunities.

A fresh viewpoint: Catalyst Pharmaceuticals

Regulatory bodies have been actively reviewing and updating financial regulations to ensure they are effective in preventing money laundering and terrorist financing.

The Financial Action Task Force (FATF) has identified high-risk jurisdictions, including countries with weak anti-money laundering and combating the financing of terrorism (AML/CFT) regimes.

The FATF has also recommended that financial institutions implement customer due diligence measures to verify the identity of their customers.

Financial institutions are required to report suspicious transactions to the relevant authorities, such as the Financial Intelligence Unit (FIU), which is responsible for analyzing and disseminating financial intelligence.

The FIU uses this information to identify and disrupt money laundering and terrorist financing activities.

Financial institutions are also required to maintain records of their customer transactions for a minimum of five years.

Financial institutions are prohibited from conducting business with countries or entities that are on the sanctions list.

Financial institutions are required to implement effective AML/CFT programs to prevent and detect money laundering and terrorist financing activities.

Expand your knowledge: Retained Cash Flow / Net Debt

Alnylam Pharmaceuticals has a significant amount of cash on hand, with a total of $2.86 billion in cash as of the most recent quarter.

The company's debt-to-equity ratio is extremely high, at 1,093.31%, indicating a significant amount of debt relative to its equity.

Alnylam Pharmaceuticals has generated a levered free cash flow of $85.71 million in the trailing 12 months.

Here is a summary of the company's valuation measures:

The 5 Year Return is a crucial metric in financial analysis, and it's essential to understand how it works.

A 5 Year Return is the total return on investment over a 5 year period, including dividends and capital gains.

It's calculated by taking the current price of the investment and subtracting the initial purchase price, then dividing by the initial purchase price.

For example, if you invested $10,000 in a stock that's now worth $15,000, your 5 Year Return would be 50%.

You might like: Initial Exchange Offering

In some cases, a 5 Year Return can be negative, indicating that the investment has lost value over the past 5 years.

This can be due to various factors, including market fluctuations, economic downturns, or poor investment decisions.

A 5 Year Return of 0% means that the investment has neither gained nor lost value over the past 5 years.

It's worth noting that a 5 Year Return is just one metric, and it's essential to consider other factors, such as risk and volatility, when making investment decisions.

A high 5 Year Return doesn't necessarily mean that an investment is a good choice, especially if it involves high levels of risk.

Worth a look: 5 Years

In this section, we'll explore how revenue and earnings relate to each other, using the financial data from our example company.

The company's Enterprise Value/Revenue is 23.91, which can be a useful metric for understanding how much the company is valued relative to its revenue.

This is particularly relevant when considering the company's growth prospects, as a high Enterprise Value/Revenue ratio may indicate that investors are expecting significant future growth.

Here are some key metrics that illustrate the relationship between revenue and earnings:

These metrics suggest that the company's revenue is a significant factor in its valuation, with the Enterprise Value/Revenue ratio being closely matched by the Price/Sales ratio.

Let's take a closer look at the company's Enterprise Value/Revenue ratio. A ratio of 23.91 indicates that the company's Enterprise Value is approximately 23.91 times its revenue.

This can be a useful metric for investors and analysts looking to gauge the company's valuation and growth prospects.

On a similar theme: Patricia Lopez / Bloomberg Opinion

Let's take a closer look at the financial position and cash flow of a company. The total cash on hand is a staggering $2.86 billion, a significant amount that can be used to invest in the business, pay off debts, or return to shareholders.

This cash balance is impressive, but it's also important to consider the company's debt-to-equity ratio. With a ratio of 1,093.31%, the company's debt is significantly higher than its equity, which could be a concern for investors.

The levered free cash flow is a more nuanced metric, but it gives us an idea of the company's ability to generate cash after paying off debt. At $85.71 million, this is a respectable amount that suggests the company is generating sufficient cash to meet its financial obligations.

Here's a quick snapshot of the company's financial position and cash flow:

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics, a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression.

The company has five drugs on the market, including Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Alnylam has several clinical programs across various therapeutic areas, including genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases.

Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Here are some of the therapeutic areas Alnylam is working on:

Alnylam Pharmaceuticals is a leader in the RNAi therapeutics industry, a field that's still in its early stages. Founded in 2002, the company has been at the forefront of developing innovative treatments for severe and rare diseases.

Alnylam's focus on RNAi therapeutics has led to the development of several treatments, including Onpattro, which was approved in 2018 for the treatment of polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.

The company's commitment to advancing RNAi therapeutics has positioned it for long-term growth and success in the industry.

Alnylam Pharmaceuticals, Inc. is a biotech company that discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.

Its commercialized product portfolio includes ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, OXLUMO for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

The company had 18 potential treatments in various development stages in genetic medicine, cardiometabolic disease, and hepatic infectious disease as of 2016.

Alnylam's lead candidate in phase III studies in 2016 was patisiran, a treatment targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).

Patisiran, now known as Onpattro, received U.S. regulatory approval in August 2018 to treat polyneuropathy in patients with hereditary ATTR amyloidosis.

The company has several products in various stages of development, including vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy, and Nucresiran, which is in phase I clinical trial for ATTR amyloidosis.

For your interest: Docusign Free Trial Limitations

The industry analytics scene is a complex one, with various metrics at play.

Key performance indicators (KPIs) such as revenue growth and customer acquisition rates are crucial for businesses to gauge their success.

According to recent data, the average revenue growth for companies in the industry is around 15%.

In the past year, customer acquisition rates have increased by 20%.

This is largely due to the rise of digital marketing, which has made it easier for businesses to reach their target audience.

The use of data analytics tools has also become more widespread, allowing companies to make more informed decisions.

For instance, a recent survey found that 80% of businesses use data analytics to inform their marketing strategies.

Worth a look: Do Businesses Prefer Cash or Credit

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. This naturally occurring biological pathway within cells helps regulate gene expression.

The company has five drugs on the market, including Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Alnylam's research partnerships have boosted their cash levels with upfront fees, and they're set to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Here are Alnylam's five drugs on the market:

Alnylam Pharmaceuticals is a biopharmaceutical company that focuses on developing RNA interference (RNAi) therapeutics.

Founded in 2002, the company has grown to become a leader in the field of RNAi-based medicines.

Alnylam's headquarters are located in Cambridge, Massachusetts, and the company has a global presence with offices in several countries.

The company's mission is to harness the power of RNAi to deliver innovative treatments to patients with devastating diseases.

Alnylam Pharmaceuticals Inc is a company with a notable product portfolio. Patisiran, one of their commercialized products, was approved by the FDA in 2018 as the first RNA interference therapeutic for hereditary ATTR amyloidosis polyneuropathy.

The FDA has raised doubts about the efficacy of patisiran for treating cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR-CM). The FDA's Cardiovascular and Renal Drugs Advisory Committee meeting is scheduled for September 13, 2023.

A decision on Alnylam's application for patisiran in ATTR-CM treatment is expected by October 8, 2023.

A fresh viewpoint: Fda Firings Doge

Employees at Alnylam Pharmaceuticals are based in various locations across the US.

Alnylam Pharmaceuticals has a presence in several states, including Massachusetts, California, Illinois, and New Jersey.

Biotechnology research facilities are located in Boston, MA, Cambridge, MA, and Thousand Oaks, CA.

Pharmaceutical manufacturing takes place in North Chicago, Illinois, Cambridge, MA, San Diego, California, and Lawrence Township, NJ.

Here's a breakdown of the locations where Alnylam Pharmaceuticals employees are based: